Pharmaceutical company sponsorship of doctors: is gender equity a concern?

Article Public, Environmental & Occupational Health

International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency

Piotr Ozieranski et al.

Summary: This study compares the self-regulation of payment disclosure in the UK and Japan and finds that they have both shared and unique strengths and weaknesses. It suggests that self-regulation can be enhanced and eventually replaced by public regulation to increase transparency and accountability.

GLOBALIZATION AND HEALTH (2023)

Add to Collection

Letter Medicine, General & Internal

Financial support provided to male and female physicians by pharmaceutical companies in New Zealand: a cross-sectional study

Leah Jones

MEDICAL JOURNAL OF AUSTRALIA (2023)

Add to Collection

Article Health Policy & Services

Drugs to avoid to improve quality use of medicines: how is Australia faring?

Agnes Vitry et al.

Summary: The French bulletin Prescrire annually publishes a list of drugs to avoid, which was assessed in terms of approval, reimbursement, and usage in Australia. Results showed that 16 harmful drugs included in the list were being substantially used in Australia, prompting a need for regulatory and reimbursement agencies to review the status of these drugs.

JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE (2021)

Add to Collection

Review Medicine, General & Internal

Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? A Systematic Review

Aaron P. Mitchell et al.

Summary: The study found that financial payments from the drug industry to U.S. physicians are associated with physician prescribing practices, including increased prescribing of the paying company's drug, increased prescribing costs, and increased prescribing of branded drugs.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Article Health Care Sciences & Services

Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries

Shai Mulinari et al.

Summary: This study conducted a comparative analysis of payment disclosures of 20 large pharmaceutical companies in seven European countries from 2017 to 2019, revealing significant differences in payment patterns between countries and companies. The research supports the implementation of a Europe-wide Sunshine Act to achieve real transparency in drug company payments.

HEALTH POLICY (2021)

Add to Collection

Article Medicine, General & Internal